Laurence Hatteville
Overview
Explore the profile of Laurence Hatteville including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trneny M, Verhoef G, Dyer M, Yehuda D, Patti C, Canales M, et al.
Haematologica
. 2018 May;
103(8):1351-1358.
PMID: 29748443
This phase II, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented ( or transformed) relapsed or...
2.
Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, et al.
Br J Haematol
. 2016 Mar;
173(5):722-30.
PMID: 27010483
In this phase II, multicentre, single-arm study, 52 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) received the anti-CD19 antibody-drug conjugate coltuximab ravtansine (55 mg/m(2) ) and rituximab (375 mg/m(2)...
3.
Kantarjian H, Lioure B, Kim S, Atallah E, Leguay T, Kelly K, et al.
Clin Lymphoma Myeloma Leuk
. 2016 Jan;
16(3):139-45.
PMID: 26775883
Background: Long-term disease-free survival in adult patients with acute lymphoblastic leukemia (ALL) remains unsatisfactory, and the treatment options are limited for those patients with relapse or a failure to respond...
4.
Ribrag V, Dupuis J, Tilly H, Morschhauser F, Laine F, Houot R, et al.
Clin Cancer Res
. 2013 Oct;
20(1):213-20.
PMID: 24132920
Purpose: To determine recommended dose, dose-limiting toxicity, safety profile, pharmacokinetics, preliminary antitumor activity, and exploratory pharmacodynamics of SAR3419, an antibody-drug conjugate targeting CD19, administered alone by intravenous infusion weekly (qw),...
5.
Tannock I, Fizazi K, Ivanov S, Thellenberg Karlsson C, Flechon A, Skoneczna I, et al.
Lancet Oncol
. 2013 Jun;
14(8):760-8.
PMID: 23742877
Background: Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF...
6.
Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, et al.
Eur J Cancer
. 2013 May;
49(12):2633-42.
PMID: 23642329
Background: This phase III study investigated the addition of aflibercept to gemcitabine, in patients with advanced pancreatic cancer. Patients And Methods: Patients with metastatic pancreatic cancer were randomly assigned to...
7.
Hatteville L, Mahe C, Hill C
Stat Med
. 2002 Sep;
21(16):2345-54.
PMID: 12210619
After a breast cancer diagnosis, single or multiple events can occur during follow-up (recurrence, metastasis, and death). An analysis of long-term survival should take into account not only the initial...